Human papillomavirus DNA methylation as a potential biomarker for cervical cancer

Megan A. Clarke, Nicolas Wentzensen, Lisa Mirabello, Arpita Ghosh, Sholom Wacholder, Ariana Harari, Attila Lorincz, Mark Schiffman, Robert D. Burk

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNAmethylation in cervical carcinogenesis, and discuss the merits of different methods used to measureHPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.

Original languageEnglish (US)
Pages (from-to)2125-2137
Number of pages13
JournalCancer Epidemiology Biomarkers and Prevention
Volume21
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

DNA Methylation
Uterine Cervical Neoplasms
Biomarkers
Cervical Intraepithelial Neoplasia
Papillomavirus Infections
Methylation
Nucleic Acid Regulatory Sequences
Viral DNA
Carcinogenesis
DNA
Genes
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. / Clarke, Megan A.; Wentzensen, Nicolas; Mirabello, Lisa; Ghosh, Arpita; Wacholder, Sholom; Harari, Ariana; Lorincz, Attila; Schiffman, Mark; Burk, Robert D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 21, No. 12, 12.2012, p. 2125-2137.

Research output: Contribution to journalArticle

Clarke, MA, Wentzensen, N, Mirabello, L, Ghosh, A, Wacholder, S, Harari, A, Lorincz, A, Schiffman, M & Burk, RD 2012, 'Human papillomavirus DNA methylation as a potential biomarker for cervical cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 12, pp. 2125-2137. https://doi.org/10.1158/1055-9965.EPI-12-0905
Clarke, Megan A. ; Wentzensen, Nicolas ; Mirabello, Lisa ; Ghosh, Arpita ; Wacholder, Sholom ; Harari, Ariana ; Lorincz, Attila ; Schiffman, Mark ; Burk, Robert D. / Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2012 ; Vol. 21, No. 12. pp. 2125-2137.
@article{e6d895bce5a6419ba4d7bfb09955abda,
title = "Human papillomavirus DNA methylation as a potential biomarker for cervical cancer",
abstract = "Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNAmethylation in cervical carcinogenesis, and discuss the merits of different methods used to measureHPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.",
author = "Clarke, {Megan A.} and Nicolas Wentzensen and Lisa Mirabello and Arpita Ghosh and Sholom Wacholder and Ariana Harari and Attila Lorincz and Mark Schiffman and Burk, {Robert D.}",
year = "2012",
month = "12",
doi = "10.1158/1055-9965.EPI-12-0905",
language = "English (US)",
volume = "21",
pages = "2125--2137",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Human papillomavirus DNA methylation as a potential biomarker for cervical cancer

AU - Clarke, Megan A.

AU - Wentzensen, Nicolas

AU - Mirabello, Lisa

AU - Ghosh, Arpita

AU - Wacholder, Sholom

AU - Harari, Ariana

AU - Lorincz, Attila

AU - Schiffman, Mark

AU - Burk, Robert D.

PY - 2012/12

Y1 - 2012/12

N2 - Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNAmethylation in cervical carcinogenesis, and discuss the merits of different methods used to measureHPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.

AB - Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNAmethylation in cervical carcinogenesis, and discuss the merits of different methods used to measureHPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.

UR - http://www.scopus.com/inward/record.url?scp=84871263662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871263662&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-12-0905

DO - 10.1158/1055-9965.EPI-12-0905

M3 - Article

C2 - 23035178

AN - SCOPUS:84871263662

VL - 21

SP - 2125

EP - 2137

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -